Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Al-Ola Abdallah, Andrew J Cowan, Xavier Leleu, Cyrille Touzeau, Brea Lipe, Eva Medvedova, Caitlin Costello, Jens Hillengass, P. Leif Bergsagel, Raya Mawad, Henning Schade, Daniel Morillo Giles, Albert Oriol, Yifah Yaron, Patrick P Ng, Sumit Madan

Blood (2022) 140 (Supplement 1): 7284–7285.

https://doi.org/10.1182/blood-2022-159665

Published: 2022

Journal Articles

The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma

Patrick P Ng, Wade Aaron, Evan Callihan, Golzar Hemmati, Che-Leung Law, Abdel Kareem Azab, Laura Sun

Blood (2021) 138 (Supplement 1): 1185.

https://doi.org/10.1182/blood-2021-151880

Published: 2021

Journal Articles

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

V. Koneti Koneti Rao, MD FRCPA, Patrick P. Ng, PhD, Craig M. Hill, PhD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137631

Published: 2020

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Patrick P. Ng, Daniel K. Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Y. Chang, PhD

Blood (2015) 126 (23): 3998.

https://doi.org/10.1182/blood.V126.23.3998.3998

Published: 2015

Journal Articles

B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)–infected patients rarely react with the viral proteins

Patrick P. Ng, Chiung-Chi Kuo, Stanley Wang, Shirit Einav, Luca Arcaini, Marco Paulli, Carol S. Portlock, Joseph Marcotrigiano, Alexander Tarr, Jonathan Ball, Ronald Levy, Shoshana Levy

Blood (2014) 123 (10): 1512–1515.

https://doi.org/10.1182/blood-2013-10-532895

Published: 2014

Journal Articles

Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy

James A Torchia, Patrick P Ng, PhD, Homer Chen, Holbrook E Kohrt, MD, PhD, Aurelien Marabelle, MD, MSc, Ash A. Alizadeh, MD, PhD, Ronald Levy, MD

Blood (2012) 120 (21): 3713.

https://doi.org/10.1182/blood.V120.21.3713.3713

Published: 2012

Journal Articles

Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma.

Patrick P. Ng, Ming Jia, Alejandro Virrueta, Kedar Patel, James R. Swartz, Shoshana Levy, Ronald Levy

Blood (2009) 114 (22): 2712.

https://doi.org/10.1182/blood.V114.22.2712.2712

Published: 2009

Journal Articles

Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor

Patrick P. Ng, Gustavo Helguera, Tracy R. Daniels, Simon Z. Lomas, Jose A. Rodriguez, Gary Schiller, Benjamin Bonavida, Sherie L. Morrison, Manuel L. Penichet

Blood (2006) 108 (8): 2745–2754.

https://doi.org/10.1182/blood-2006-04-020263

Published: 2006

Includes: Supplemental data

NARROW

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)–infected patients rarely react with the viral proteins

Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy

Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma.

Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only